Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is considered one of the cheap healthcare stocks to buy heading into 2026. Analysts rate it as a consensus Buy with a median price target of $35, representing a 48.75% upside potential. Chief Commercial Officer Jeffrey Del Carmen recently sold over 10,000 shares of CPRX.

At a recent healthcare conference, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) emphasized plans to advance education in oncology for LEMS. The company aims to target patients at different diagnostic stages for organic growth. Despite competition in the epilepsy market, CPRX remains dedicated to patient support and strategic acquisitions.

Founded in 2002, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based biopharmaceutical company providing treatments for life-threatening diseases. They offer products like Firdapse, Fycompa, Ruzurgi, and AGAMREE. While CPRX shows investment potential, some AI stocks may offer greater upside with less downside risk.

For more insights on investment opportunities, consider exploring our free report on the best short-term AI stock. Stay informed on market trends and potential growth opportunities by reading about the Best and Worst Dow Stocks for the Next 12 Months. Disclosure: None.

Read more at Yahoo Finance: Analysts See Big Upside in Catalyst Pharmaceuticals, Inc. (CPRX)